Efficacy and safety of the third-generation tyrosine kinase inhibitor Olverembatinib in relapsed and persistent minimal residual disease positive Philadelphia chromosome-positive acute lymphoblastic leukemia patients
The efficacy and tolerability of Olverembatinib were confirmed in patients with relapsed, MRD-positive, Ph + ALL, offering a novel therapeutic approach for these patients and making prolonged survival possible.
Authors
- Sai Ma (ORCID: https://orcid.org/0000-0002-1435-6716)
- Minran Zhou (ORCID: https://orcid.org/0000-0001-6735-7758)
- Qingli Ji (ORCID: https://orcid.org/0009-0008-6311-5688)
- Xinwen Jiang (ORCID: https://orcid.org/0009-0004-6928-263X)
- Xiaoqing Li (ORCID: https://orcid.org/0000-0002-9815-6040)
- MA Junjie
- Chunyan Chen (ORCID: https://orcid.org/0000-0002-5919-7624)
Institutions
- Yuhuangding Hospital (CN)
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-10-03
- DOI
- https://doi.org/10.3389/fmed.2025.1662512
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00